News

Find News

Filter articles

Applied Filters

Showing 61 to 70 of 642 results

SPC waiver stockpiling provision attracts criticism

EU19-02-2019

While the final text of the European Council’s agreement on a supplementary protection certificate manufacturing waiver has yet to be released, the reported stockpiling provision has attracted criticism.

CJEU backs Warner-Lambert in marketing authorisation dispute

Netherlands18-02-2019

The Court of Justice of the European Union has issued a judgment in favour of Warner-Lambert amid a dispute between the American pharmaceutical company and an administrative body in the Netherlands.

EU court rejects Bayer’s heart-related TM

EU14-02-2019

Bayer suffered defeat at the hands of the EU General Court today, with the rejection of its attempt to register what the court deemed to be heart-related trademark.

EU court throws out dentistry TM application

EU13-02-2019

The EU General Court has dismissed an appeal from German company Nemius Group against a decision to refuse registration for its ‘Dentaldisk’ mark.

UK could lose out on Europe-wide drug safety system post-Brexit

EU, UK12-02-2019

UK patients could be more exposed to counterfeit medicines than EU patients in the event of a ‘no deal’ Brexit, because access to an initiative aimed at protecting patients from fake drugs could be lost.

GSK and Merck KGaA unite in €3.7bn immunotherapy deal

Germany, UK06-02-2019

UK headquartered GSK has made another move in the oncology space, signing a potential €3.7 billion immunotherapy deal with Germany-based Merck KGaA.

Merck signs DNA licensing deal with Vertex

Germany, US28-01-2019

German pharmaceutical company Merck Group has granted US biotech firm Vertex a licence to two DNA-dependent protein kinases inhibitors.

HGF adds IP partner in The Hague office

Netherlands22-01-2019

Law firm HGF has added Leythem Wall as a partner.

Novartis enters AI partnership with Oxford University

UK21-01-2019

Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.

Life sciences lawyers shocked and concerned amid Brexit uncertainty

UK17-01-2019

Lawyers have told LSIPR they are concerned about the continuing UK political uncertainty having a negative impact on life sciences investment and the Unified Patent Court.

Showing 61 to 70 of 642 results

LSIPR